ARB protects podocytes from HIV-1 nephropathy independently of podocyte AT1 | Zendy

Akihiro Shimizu | Zendy; Jianyong Zhong | Zendy; Yoichi Miyazaki | Zendy; Tatsuo Hosoya | Zendy; Iekuni Ichikawa | Zendy; Taiji Matsusaka | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

ARB protects podocytes from HIV-1 nephropathy independently of podocyte AT1

Author(s) -

Akihiro Shimizu,

Jianyong Zhong,

Yoichi Miyazaki,

Tatsuo Hosoya,

Iekuni Ichikawa,

Taiji Matsusaka

Publication year - 2012

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfs033

Subject(s) - nephrin , angiotensin ii receptor type 1 , podocyte , glomerulosclerosis , medicine , endocrinology , angiotensin ii , nephropathy , angiotensin receptor , renin–angiotensin system , receptor , proteinuria , kidney , diabetes mellitus , blood pressure

Angiotensin I-converting enzyme inhibitors and angiotensin receptor blockers protect podocytes more effectively than other anti-hypertensive drugs. Transgenic rats overexpressing angiotensin II Type 1 (AT1) receptor selectively in podocytes have been shown to develop glomerulosclerosis. The prevailing hypothesis is that angiotensin II has a capacity of directly acting on the AT1 receptor of podocytes to induce injury. We therefore investigated the mechanism of reno-protective effect of AT1 receptor in a mouse model of HIV-1 nephropathy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research